Astellas and Apellis are two companies competing in the U.S. to treat geographic atrophy (GA), a serious eye condition that […]

Earlier this year, EyePoint Pharmaceuticals faced setbacks when their drug-device combination, Duravyu, did not perform well in a study for

Here’s a simplified version of the text: **Key People at IQVIA** – Nancy McGee: VP of U.S. Patient Support Services

Welcome to Fierce Pharma’s 2024 regulatory tracker. We’re keeping track of the approval progress for pharmaceutical products, including their expansion

At a conference in New England, Rohan Simon, the associate director of a UAE-based contract research organization, spoke about the

LAMA2-CMD is a serious muscle disease caused by a missing protein called LAMA2, leading to early muscle weakness. The FDA

Ultra-processed foods (UPFs) in India are being linked to health issues like obesity, diabetes, heart disease, and some cancers. In

AbbVie, a pharmaceutical company, is buying Aliada Therapeutics for $1.4 billion. This purchase includes Aliada’s main experimental drug, ALIA-1758, which

A recent trial showed that nearly 60% of patients using Fasenra reached remission. The European Commission has approved Fasenra, a

At a conference on clinical trials in New England, the U.S. Customs and Border Protection (CBP) warned researchers about common